Loading...
Loading...
CYT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 11.8M |
| Operating I/L | -11.8M |
| Other Income/Expense | 0.7M |
| Interest Income | 0.0M |
| Pretax | -11.0M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | -10.3M |
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company specializing in precision oncology medicines. Their lead product, CYT-0851, is a novel, oral, once-daily, small molecule drug candidate currently in Phase I/II clinical trials for monotherapy and combination therapy in solid tumors and hematologic malignancies. Additionally, the company is developing CYT-1853, a preclinical drug for the same indications. By focusing on the development and commercialization of these next-generation precision oncology medicines, Cyteir Therapeutics aims to generate revenue through the successful advancement and eventual commercialization of their drug candidates.
